Abstract: An audible wristwatch assembly for alerting a blind user of the time of day and calendar date includes a strap that is worn around a user's wrist. The strap is extended through a housing and the housing has a recess therein. An electronic clock is positioned within the housing to track the time of day and the calendar date. A speaker is coupled to the housing to emit audible sounds outwardly from the housing. An announcement button is movably coupled to the housing, and the announcement button is positioned in the recess to inhibit the announcement button from being inadvertently depressed. The speaker audibly emits the time of day and the calendar date when the announcement button is depressed to alert the user to the time of day and the calendar date.

Abstract: An audible wristwatch assembly for alerting a blind user of the time of day and calendar date includes a strap that is worn around a user's wrist. The strap is extended through a housing and the housing has a recess therein. An electronic clock is positioned within the housing to track the time of day and the calendar date. A speaker is coupled to the housing to emit audible sounds outwardly from the housing. An announcement button is movably coupled to the housing, and the announcement button is positioned in the recess to inhibit the announcement button from being inadvertently depressed. The speaker audibly emits the time of day and the calendar date when the announcement button is depressed to alert the user to the time of day and the calendar date.

Abstract: Provided herein are cyclic nucleotide phosphodiesterase inhibitors of Formula (I) of claim 1, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Abstract: Methods and systems are provided for performing allelic copy number association in genome-wide association studies. Also provided are computer-readable media for storing instructions for performing the genomic marker association studies. The methods include performing genomic marker association studies wherein allelic contrast and copy number are analyzed simultaneously, comprising the steps of receiving measurements of intensity for each of two alleles (A and B) in a biological sample set; computing a sum value (S) and a difference value (D) of the intensities; and employing a statistical model to determine a potential association of the S and/or the D value with an outcome, wherein a statistically significant coefficient of the S intensity indicates an association of the copy number with the outcome and a statistically significant coefficient of the D intensity indicates an association of the allelic contrast with the outcome.